{"id":40357,"date":"2001-11-01T12:01:00","date_gmt":"2001-11-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien"},"modified":"2001-11-01T12:01:00","modified_gmt":"2001-11-01T11:01:00","slug":"clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/","title":{"rendered":"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien"},"content":{"rendered":"<p>Die Thienopyridinderivate Clopidogrel (Iscover, Plavix) und Ticlopidin (Tiklyd u.a.) werden bislang in Kombination mit Azetylsalizyls\u00e4ure (ASS) zur Thromboseprophylaxe nach koronarer Stentimplantation eingesetzt (s. \u00dcbersicht AMB 1999, 33, 33). Nach der CURE-Studie (Clopidogrel in Unstable angina to prevent Recurrent Events trial: N. Engl. J. Med. 2001, 345, 494) wird sich nun vermutlich die Indikation ausweiten. Ziel [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Thienopyridinderivate Clopidogrel (Iscover, Plavix) und Ticlopidin (Tiklyd u.a.) werden bislang in Kombination mit Azetylsalizyls\u00e4ure (ASS) zur Thromboseprophylaxe nach koronarer Stentimplantation eingesetzt (s. \u00dcbersicht AMB 1999, 33, 33). Nach der CURE-Studie (Clopidogrel in Unstable angina to prevent Recurrent Events trial: N. Engl. J. Med. 2001, 345, 494) wird sich nun vermutlich die Indikation ausweiten. Ziel [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[76,139,141],"class_list":["post-40357","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angina-pectoris","tag-clopidogrel","tag-cure-studie"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Die Thienopyridinderivate Clopidogrel (Iscover, Plavix) und Ticlopidin (Tiklyd u.a.) werden bislang in Kombination mit Azetylsalizyls\u00e4ure (ASS) zur Thromboseprophylaxe nach koronarer Stentimplantation eingesetzt (s. \u00dcbersicht AMB 1999, 33, 33). Nach der CURE-Studie (Clopidogrel in Unstable angina to prevent Recurrent Events trial: N. Engl. J. Med. 2001, 345, 494) wird sich nun vermutlich die Indikation ausweiten. Ziel [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2001-11-01T11:01:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/11\/Abbildung-2001-83-2.gif\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien\",\"datePublished\":\"2001-11-01T11:01:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/\"},\"wordCount\":677,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2001\\\/11\\\/Abbildung-2001-83-2.gif\",\"keywords\":[\"Angina pectoris\",\"Clopidogrel\",\"CURE-Studie\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/\",\"name\":\"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2001\\\/11\\\/Abbildung-2001-83-2.gif\",\"datePublished\":\"2001-11-01T11:01:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2001\\\/11\\\/Abbildung-2001-83-2.gif\",\"contentUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2001\\\/11\\\/Abbildung-2001-83-2.gif\",\"width\":500,\"height\":309},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/","og_locale":"de_DE","og_type":"article","og_title":"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien - Der Arzneimittelbrief","og_description":"Die Thienopyridinderivate Clopidogrel (Iscover, Plavix) und Ticlopidin (Tiklyd u.a.) werden bislang in Kombination mit Azetylsalizyls\u00e4ure (ASS) zur Thromboseprophylaxe nach koronarer Stentimplantation eingesetzt (s. \u00dcbersicht AMB 1999, 33, 33). Nach der CURE-Studie (Clopidogrel in Unstable angina to prevent Recurrent Events trial: N. Engl. J. Med. 2001, 345, 494) wird sich nun vermutlich die Indikation ausweiten. Ziel [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2001-11-01T11:01:00+00:00","og_image":[{"url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/11\/Abbildung-2001-83-2.gif","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien","datePublished":"2001-11-01T11:01:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/"},"wordCount":677,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/11\/Abbildung-2001-83-2.gif","keywords":["Angina pectoris","Clopidogrel","CURE-Studie"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/","name":"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/11\/Abbildung-2001-83-2.gif","datePublished":"2001-11-01T11:01:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/#primaryimage","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/11\/Abbildung-2001-83-2.gif","contentUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/11\/Abbildung-2001-83-2.gif","width":500,"height":309},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40357"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40357\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}